Please login to the form below
BCMA
This page shows the latest BCMA news and features for those working in and with pharma, biotech and healthcare.
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
In June, AbbVie exercised a right to acquire TeneoOne – a Teneobio affiliate – which includes adding an anti-CD3/BCMA bispecific TNB-383B candidate for the treatment of relapsed or refractory multiple
Latest news
-
FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy
The investigational B-cell maturation antigen (BCMA) CAR T therapy, also known as cilta-cel, is backed by results from the phase 1b/2 CARTITUDE-1 study.
-
bluebird bio aiming to separate business units by year-end
2seventy bio will assume responsibility for a number of bluebird bio’s oncology assets, such as its Bristol Myers Squibb(BMS) partnered BCMA-targeted CAR T cell immunotherapy Abecma (idecabtagene vicleucel;
-
Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody
Pfizer has paused enrolment for a phase 2 trial evaluating its anti-BCMA bispecific antibody elranatamab, following three cases of peripheral neuropathy in an ongoing phase 1 study. ... The company announced the pause for the MagnetisMM-3 trial, which is
-
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel – for the
-
bluebird bio to separate oncology and rare diseases units
Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will
FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy
bluebird bio aiming to separate business units by year-end
Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
More from news
Approximately 6 fully matching, plus 52 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... BCMA to which Celgene already has access.
Deal Watch September 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Highlights in haematologic malignancy from ASH 2018
Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
